Itau Unibanco Holding S.A. Has $1.27 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Itau Unibanco Holding S.A. increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 118.5% during the third quarter, Holdings Channel.com reports. The institutional investor owned 16,294 shares of the company’s stock after purchasing an additional 8,837 shares during the period. Itau Unibanco Holding S.A.’s holdings in AstraZeneca were worth $1,269,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Martin Investment Management LLC grew its stake in AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after buying an additional 7,615 shares during the last quarter. Integrated Advisors Network LLC increased its stake in shares of AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after purchasing an additional 13,860 shares during the period. Creative Planning boosted its stake in AstraZeneca by 8.0% in the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after purchasing an additional 16,692 shares during the period. Northcape Wealth Management LLC acquired a new stake in shares of AstraZeneca during the second quarter worth $269,000. Finally, Optas LLC boosted its position in shares of AstraZeneca by 173.5% in the third quarter. Optas LLC now owns 15,570 shares of the company’s stock valued at $1,213,000 after acquiring an additional 9,877 shares during the period. 20.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on AZN shares. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. TD Cowen increased their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $67.04 on Tuesday. The company’s 50 day moving average price is $72.27 and its two-hundred day moving average price is $77.44. The firm has a market capitalization of $207.86 billion, a P/E ratio of 32.08, a P/E/G ratio of 1.24 and a beta of 0.45. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the company earned $0.87 earnings per share. The business’s quarterly revenue was up 18.0% on a year-over-year basis. On average, equities analysts forecast that AstraZeneca PLC will post 4.1 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.